Laura R. Evangelista

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: July 15, 2026

Integrating PSMA PET into urological practice: insights from a multidisciplinary Italian survey.

Journal: Minerva urology and nephrology

Published: June 19, 2026

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Journal: Expert review of gastroenterology & hepatology

Published: June 08, 2026

Efficacy, safety, and quality of life outcomes of [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.

Journal: International urology and nephrology

Published: June 04, 2026

Non-FDG PET/CT.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

Published: May 21, 2026

Response assessment in [177Lu]PSMA: where do we stand?

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: May 14, 2026

Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.

Journal: Cancers

Published: May 08, 2026

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 25, 2026

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

Journal: BJU international

Published: April 20, 2026

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 20, 2026

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Integrating PSMA PET into urological practice: insights from a multidisciplinary Italian survey.

Integrating PSMA PET into urological practice: insights from a multidisciplinary Italian survey.

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Efficacy, safety, and quality of life outcomes of [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.

Efficacy, safety, and quality of life outcomes of [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.

Non-FDG PET/CT.

Non-FDG PET/CT.

Response assessment in [177Lu]PSMA: where do we stand?

Response assessment in [177Lu]PSMA: where do we stand?

Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.

Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

Re: PSMA PET for Lymph Nodes in Intermediate-risk PC.

Re: PSMA PET for Lymph Nodes in Intermediate-risk PC.

PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [18F] Piflufolastat PSMA PET/CT.

PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [18F] Piflufolastat PSMA PET/CT.

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.